(Q35035596)

5 August 2017

title

Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer (English)

1 reference

5 August 2017

main subject

metastatic breast cancer

1 reference

1 reference

1 reference

10

Vered Stearns

1 reference

5 August 2017

8

John H Fetting

1 reference

5 August 2017

Roisin M Connolly

1

1 reference

5 August 2017

Michelle A Rudek

2

1 reference

5 August 2017

Elizabeth Garrett-Mayer

3

1 reference

5 August 2017

Stacie C Jeter

4

1 reference

5 August 2017

Michele G Donehower

5

1 reference

5 August 2017

Laurie A Wright

6

1 reference

5 August 2017

Ming Zhao

7

1 reference

5 August 2017

Leisha A Emens

9

1 reference

5 August 2017

Nancy E Davidson

11

1 reference

5 August 2017

Sharyn D Baker

12

1 reference

5 August 2017

Antonio C Wolff

13

1 reference

5 August 2017

language of work or name

English

0 references

publication date

25 February 2011

1 reference

Breast Cancer Research and Treatment

5 August 2017

published in

1 reference

5 August 2017

volume

127

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

153-162

1 reference

Adjuvant docetaxel for high-risk, node-negative breast cancer

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Influence of solute carriers on the pharmacokinetics of CYP3A4 probes.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Pharmacogenetic pathway analysis of docetaxel elimination.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Effects of inflammation on pharmacokinetics/pharmacodynamics: increasing recognition of its contribution to variability in response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Interaction of imatinib with human organic ion carriers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Weekly paclitaxel in the adjuvant treatment of breast cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

A quantitative analysis of kinase inhibitor selectivity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Clinical pharmacokinetics of imatinib

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Population pharmacokinetics of weekly docetaxel in patients with advanced cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Preclinical evaluation of docetaxel (Taxotere).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Adjuvant docetaxel for node-positive breast cancer

8 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Factors affecting cytochrome P-450 3A activity in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Inhibition of imatinib transport by uremic toxins during renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Effects of uptake and efflux transporter inhibition on erythromycin breath test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3111459

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

25 October 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-011-1413-6

Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma

21 January 2018

1 reference

12 December 2020

Tyrosine kinases as targets for cancer therapy

1 reference

12 December 2020

Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype

1 reference

12 December 2020

The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance

1 reference

12 December 2020

10.1007/S10549-011-1413-6

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/npkcqt3gmfhs5isnw54vwdsvlu

30 July 2022

release_npkcqt3gmfhs5isnw54vwdsvlu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/npkcqt3gmfhs5isnw54vwdsvlu

30 July 2022

https://api.fatcat.wiki/v0/release/npkcqt3gmfhs5isnw54vwdsvlu

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/npkcqt3gmfhs5isnw54vwdsvlu

1 reference

30 July 2022